Trauma to the Skin, Subcutaneous Tissue and Breast DRG Reimbursement

DRG 604 addresses inpatient cases of trauma to the skin, subcutaneous tissue, and breast with a Major Complication or Comorbidity, reflecting higher clinical complexity. This grouping matters for inpatient reimbursement because the presence of a Major Complication or Comorbidity increases resource intensity and influences Medicare payment rates.

DRG 604 Overview

DRG 604 covers inpatient admissions for trauma to the skin, subcutaneous tissue, and breast when a Major Complication or Comorbidity is present, indicating more severe clinical complexity. These cases often involve extensive wound management, infection control, debridement, reconstructive procedures, or management of systemic complications, which increase resource use. This Diagnosis-Related Group matters for Medicare payment because the presence of a Major Complication or Comorbidity elevates reimbursement relative to less severe groupings to reflect higher expected costs of care. Accurate clinical documentation and coding determine assignment to this Diagnosis-Related Group and therefore affect payment.

Acute surgical intervention trials: randomized or prospective cohort studies comparing different surgical wound management strategies for patients admitted with severe traumatic injuries to the skin, subcutaneous tissue, or breast complicated by major comorbid conditions (eg, diabetes, peripheral vascular disease, immunosuppression). These studies enroll inpatients presenting with complex soft-tissue trauma requiring debridement, closure, or reconstructive procedures, and evaluate outcomes such as infection rates, time to wound closure, need for reoperation, and hospital length of stay. Results inform surgical decision-making and resource use, which directly affect reimbursement, coding accuracy, and inpatient cost management for this high-acuity DRG.
Comparative effectiveness research on infection prevention and antibiotic stewardship: pragmatic trials or observational comparative studies assessing perioperative and inpatient antibiotic regimens, topical antiseptics, or negative-pressure wound therapy in patients with traumatic skin and subcutaneous injuries and significant comorbidities that increase infection risk. These studies focus on heterogeneous real-world inpatient populations to determine which prevention strategies reduce surgical site infections, sepsis, and readmissions while minimizing antibiotic overuse. Findings are relevant to clinicians for optimizing care pathways and to payers for reducing costly complications and avoiding extended stays associated with major complication or comorbidity (MCC) classifications.
Post-discharge outcomes and recovery studies: longitudinal cohort studies and registries tracking functional recovery, wound healing trajectories, quality of life, and healthcare utilization (eg, readmissions, outpatient visits, home health needs) among survivors of traumatic skin/subcutaneous/breast injuries with MCCs. These studies often stratify by injury severity, comorbidity burden, and index inpatient treatments to identify predictors of long-term disability, need for reconstructive follow-up, and total episode-of-care costs. Understanding post-discharge outcomes helps providers plan discharge resources and care coordination and enables payers to model bundled payments, case management needs, and potential interventions that reduce downstream costs associated with this DRG.

Acute surgical intervention trials: randomized or prospective cohort studies comparing different surgical wound management strategies for patients admitted with severe traumatic injuries to the skin, subcutaneous tissue, or breast complicated by major comorbid conditions (eg, diabetes, peripheral vascular disease, immunosuppression). These studies enroll inpatients presenting with complex soft-tissue trauma requiring debridement, closure, or reconstructive procedures, and evaluate outcomes such as infection rates, time to wound closure, need for reoperation, and hospital length of stay. Results inform surgical decision-making and resource use, which directly affect reimbursement, coding accuracy, and inpatient cost management for this high-acuity DRG.
Comparative effectiveness research on infection prevention and antibiotic stewardship: pragmatic trials or observational comparative studies assessing perioperative and inpatient antibiotic regimens, topical antiseptics, or negative-pressure wound therapy in patients with traumatic skin and subcutaneous injuries and significant comorbidities that increase infection risk. These studies focus on heterogeneous real-world inpatient populations to determine which prevention strategies reduce surgical site infections, sepsis, and readmissions while minimizing antibiotic overuse. Findings are relevant to clinicians for optimizing care pathways and to payers for reducing costly complications and avoiding extended stays associated with major complication or comorbidity (MCC) classifications.
Post-discharge outcomes and recovery studies: longitudinal cohort studies and registries tracking functional recovery, wound healing trajectories, quality of life, and healthcare utilization (eg, readmissions, outpatient visits, home health needs) among survivors of traumatic skin/subcutaneous/breast injuries with MCCs. These studies often stratify by injury severity, comorbidity burden, and index inpatient treatments to identify predictors of long-term disability, need for reconstructive follow-up, and total episode-of-care costs. Understanding post-discharge outcomes helps providers plan discharge resources and care coordination and enables payers to model bundled payments, case management needs, and potential interventions that reduce downstream costs associated with this DRG.

OpenPayer

Summary & Overview

Trauma to the Skin, Subcutaneous Tissue and Breast with MCC: Inpatient Reimbursement Overview

DRG 604 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes